Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Radiation Therapy leaders gather for ProteusONE demonstration

IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce that today 60 radiation therapy leaders travelled to Belgium to discover the first Proteus®ONE in factory.

June 3, 2013

Patients and Technologists Benefit from Reduced Dose of UltraSPECT Image Reconstruction Software

UltraSPECT, a leading provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announces today the installation of its proprietary Wide Beam Reconstruction (WBR™) software at nearly ten healthcare facilities.

May 30, 2013

Cleveland researchers launch Amyvid study

A team of radiologists and neurologists at University Hospitals Case Medical Center in Cleveland are enrolling patients with suspected early-stage Alzheimer’s disease in a study designed to determine if Amyvid can identify amyloid plaques via PET or MRI. Read more about the research by clicking the link below.

May 30, 2013

Texas Children's Hospital is the first children's hospital in the nation to offer PET/MRI scanner to better diagnose several childhood diseases

Texas Children's Hospital announced today that it is the first children's hospital in the United States to begin using a PET/MRI (positron emission tomography/magnetic resonance imaging) scanner, a state-of-the-art technology that will help in early and accurate diagnosis of various cancers, heart diseases and degenerative neurological disorders. Texas Children's is also the only hospital in the Texas Medical Center to have this machine.

May 9, 2013

Phase III Alzheimer’s treatment study misses the mark

Baxter announced results of its Phase III clinical study of immunoglobulin (IG). In the randomized, double-blind, placebo-controlled, multi-center trial, IG did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease after 18 months of treatment. Given the findings, Baxter said it will re-evaluate its approach for its Alzheimer’s program.

May 7, 2013

MILabs Introduces New Benchtop Product Line

MILabs, B.V. the Netherlands‐based innovator and manufacturer of pre‐clinical SPECT/PET/CT imaging devices used in biomedical research, today announces the release of the new mini product family ‐ an easy‐to‐use series of benchtop SPECT and PET imagers for small animals that combine simplified workflow, compact dimensions and affordable pricing to bring high‐performance SPECT/PET within everyone’s reach.

May 6, 2013

Lantheus Medical Imaging to Proceed with Flurpiridaz F 18 Phase 3 Clinical Program Based on Interim Analysis of Data from First Phase 3 Study

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced an important milestone for its Phase 3 flurpiridaz F 18 clinical program.

May 1, 2013

Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek

Navidea Biopharmaceuticals, Inc. (NYSE MKT:  NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the U.S. launch of Lymphoseek® (technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma.

May 1, 2013

Around the web

Two advanced algorithms—one for CAC scores and another for segmenting cardiac chamber volumes—outperformed radiologists when assessing low-dose chest CT scans. 

"Gen AI can help tackle repetitive tasks and provide insights into massive datasets, saving valuable time," Thomas Kurian, CEO of Google Cloud, said Tuesday. 

SCAI and four other major healthcare organizations signed a joint letter in support of intravascular ultrasound. 

Trimed Popup
Trimed Popup